Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor.

Antineutrophil cytoplasmic auto-antibodies-associated vasculitis Biomarker Eosinophilic granulomatosis with polyangiitis Rheumatoid factor

Journal

Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 14 03 2019
accepted: 05 07 2019
revised: 21 05 2019
pubmed: 19 7 2019
medline: 9 4 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

To investigate the relevance of RF in patients with EGPA, we reviewed consecutive patients who were newly diagnosed with EGPA from August 1998 to February 2019 in Keio University Hospital with RF titer at diagnosis available. We divided the patients according to the median level of RF titer of 75 IU/mL and compared clinical features between the two groups. Among 16 patients identified, 8 patients were in the RF high group and the other 8 patients were in the RF low group. All patients in the high RF group were negative for MPO-ANCA, whereas all in the low RF group was positive for MPO-ANCA with a mean titer of 103 IU/mL. The eosinophil count at diagnosis was significantly higher in the RF high group than the RF low group (20001/μL vs 5144/μL, p < 0.01). Gastrointestinal lesion was significantly more frequent in the RF high group, and parenchymal organ lesions, such as heart and renal organ involvement, were frequent in the RF low group. With principal component analysis, RF high and low groups were clearly divided by the combination of eosinophil count, MPO-ANCA titer, gastrointestinal lesions, musculoskeletal symptoms, and disease activity score. Those results suggest EGPA can be divided into two groups in association with RF.Key Points• Our study showed that patients with EGPA can be separated into two groups according to RF titer.• The two subtypes reflect different underlying pathogenesis in EGPA, and the optimal treatment for them may be different.

Identifiants

pubmed: 31317422
doi: 10.1007/s10067-019-04680-5
pii: 10.1007/s10067-019-04680-5
doi:

Substances chimiques

Rheumatoid Factor 9009-79-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3493-3499

Références

J Allergy Clin Immunol. 2019 Jan;143(1):190-200.e20
pubmed: 30205189
Ann Rheum Dis. 2007 Feb;66(2):222-7
pubmed: 16901958
Arthritis Rheum. 2013 Jan;65(1):270-81
pubmed: 23044708
Arthritis Rheum. 2005 Sep;52(9):2926-35
pubmed: 16142760
J Asthma. 2020 Jan;57(1):82-86
pubmed: 30444149
Allergol Int. 2017 Apr;66(2):332-337
pubmed: 27592398
N Engl J Med. 2017 May 18;376(20):1921-1932
pubmed: 28514601
Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S90-7
pubmed: 24854378
Ann Intern Med. 2005 Nov 1;143(9):632-8
pubmed: 16263885
Respirology. 2006 Nov;11(6):830-2
pubmed: 17052317
Ann Rheum Dis. 2009 Dec;68(12):1827-32
pubmed: 19054820
Clin Rheumatol. 2018 Oct;37(10):2771-2779
pubmed: 29119480
Nat Rev Immunol. 2008 Mar;8(3):218-30
pubmed: 18274559
Am J Pathol. 2015 Jan;185(1):172-84
pubmed: 25452118
Arthritis Rheum. 1990 Aug;33(8):1135-6
pubmed: 2202312
Nat Rev Rheumatol. 2014 Aug;10(8):474-83
pubmed: 25003763
Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S41-7
pubmed: 24854371

Auteurs

Jun Inamo (J)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yuko Kaneko (Y)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. ykaneko.z6@keio.jp.

Yuichiro Ota (Y)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Tsutomu Takeuchi (T)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH